Class Action Commenced against Manufacturer of Oxycontin(R)



    TORONTO, June 14 /CNW/ - On June 8, 2007, the law firms of Rochon Genova
LLP and Siskinds LLP issued a class action on behalf of persons in Canada,
other than in Québec, who were prescribed and who ingested Oxycontin(R)
against the manufacturers of Oxycontin(R), Purdue Pharma, Purdue Pharma Inc.,
Purdue Frederick Inc., The Purdue Frederick Company, Inc. and Purdue Pharma LP
(the "Defendants").
    The claim, filed with the Ontario Superior Court of Justice, alleges that
the Defendants knew or ought to have known that ingesting Oxycontin(R) leads
to drug dependency and addiction. Oxycontin(R) is a narcotic frequently
prescribed as a pain-killer. It was approved for use in Canada in 1996. The
serious problems associated with ingesting Oxycontin(R) are alleged to have
been well-known to the Defendants for several years. In May 2007, Purdue
Pharma LP and some of its senior executives agreed to pay over $600 million in
penalties in the United States for misleading consumers and physicians about
the addictive properties of Oxycontin(R). Some of those senior executives also
pleaded guilty to criminal charges in the United States.
    The Proposed Representative Plaintiffs include three individuals who were
prescribed Oxycontin(R) as a pain medication following serious injuries and
who developed addictions and their family members. Colin MacKay said,
"Oxycontin(R) cost me my marriage and my kids. I now have to take another drug
to help me wean off Oxycontin(R). If I had known that I would develop a drug
addiction, I would never have taken this drug." Sabine Reid, the wife of Tim
Reid, who also became addicted to Oxycontin(R), said, "It has been an
incredibly painful process to watch my husband develop a drug addiction and
now have to go through detoxification. I never thought a pain-killer would
have this kind of dangerous effect. It has been devastating."
    "Oxycontin(R) addictions are destructive to the lives of these persons
and their families. The worst part of it is that had the manufacturers been
forthcoming, these addictions could have been prevented," said Joel P. Rochon,
a partner at Rochon Genova LLP. Michael Peerless, a partner at Siskinds LLP
added, "It is unbelievable that these companies did nothing to prevent the
harm to the class members when they knew of the dangers of Oxycontin(R) and,
instead, issued false and misleading information. It took a criminal
investigation to bring these facts to light."
    The allegations raised in the claim have not yet been proven in court.
The plaintiff and the prospective class members are represented by the Toronto
based law firm of Rochon Genova LLP and the London based law firm of Siskinds
LLP.





For further information:

For further information: Rochon Genova LLP, 121 Richmond St. W, Suite
900, Toronto, Ontario, M5H 2K1, Telephone: (416) 363-1867, or toll-free:
1-866-881-2292, Website address: www.rochongenova.com; Siskinds LLP, 680
Waterloo Street, London, ON, N6A 3V8, Tel: (519) 660-7872, Website address:
www.siskinds.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890